BACKGROUND: The c-Myb transcription factor is essential for the maintenance of stem-progenitor cells in bone marrow, colon epithelia, and neurogenic niches. c-Myb malfunction contributes to several types of malignancies including breast cancer. However, the function of c-Myb in the metastatic spread of breast tumors remains unexplored. In this study, we report a novel role of c-Myb in the control of specific proteases that regulate the matrix-dependent invasion of breast cancer cells. RESULTS: Ectopically expressed c-Myb enhanced migration and ability of human MDA-MB-231 and mouse 4T1 mammary cancer cells to invade Matrigel but not the collagen I matrix in vitro. c-Myb strongly increased the expression/activity of cathepsin D and matrix metalloproteinase (MMP) 9 and significantly downregulated MMP1. The gene coding for cathepsin D was suggested as the c-Myb-responsive gene and downstream effector of the migration-promoting function of c-Myb. Finally, we demonstrated that c-Myb delayed the growth of mammary tumors in BALB/c mice and affected the metastatic potential of breast cancer cells in an organ-specific manner. CONCLUSIONS: This study identified c-Myb as a matrix-dependent regulator of invasive behavior of breast cancer cells.

Department of Experimental Biology Faculty of Science Masaryk University and International Clinical Research Center CBCE St Anne's University Hospital Brno Czech Republic

Zobrazit více v PubMed

Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8:523–534. doi: 10.1038/nrc2439. PubMed DOI

Roussel M, Saule S, Lagrou C, Rommens C, Beug H, Graf T, Stehelin D. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature. 1979;281:452–455. doi: 10.1038/281452a0. PubMed DOI

Jin S, Zhao H, Yi Y, Nakata Y, Kalota A, Gewirtz AM. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. J Clin Invest. 2010;120:593–606. doi: 10.1172/JCI38030. PubMed DOI PMC

Clappier E, Cuccuini W, Kalota A, Crinquette A, Cayuela JM, Dik WA, Langerak AW, Montpellier B, Nadel B, Walrafen P. et al.The C-MYB locus is involved in chromosomal translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the translocation defining a new T-ALL subtype in very young children. Blood. 2007;110:1251–1261. doi: 10.1182/blood-2006-12-064683. PubMed DOI

Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F. et al.Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39:593–595. doi: 10.1038/ng2025. PubMed DOI

Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA. 2009;106:18740–18744. doi: 10.1073/pnas.0909114106. PubMed DOI PMC

Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992;3:723–730. PubMed

Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990;5:131–135. PubMed

Gonda TJ, Leo P, Ramsay RG. Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther. 2008;8:713–717. doi: 10.1517/14712598.8.6.713. PubMed DOI

Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, Olsson H, Trent JM, Isola J, Borg A. MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. 2000;60:5323–5328. PubMed

Drabsch Y, Ramsay RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 2010;12:R55. doi: 10.1186/bcr2614. PubMed DOI PMC

Chen L, Xu S, Zeng X, Li J, Yin W, Chen Y, Shao Z, Jin W. c-myb activates CXCL12 transcription in T47D and MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai) 2010;42:1–7. doi: 10.1093/abbs/gmp108. PubMed DOI

Quintana AM, Liu F, O'Rourke JP, Ness SA. Identification and Regulation of c-Myb Target Genes in MCF-7 Cells. BMC Cancer. 2011;11:30. doi: 10.1186/1471-2407-11-30. PubMed DOI PMC

Liu F, Lei W, O'Rourke JP, Ness SA. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. Oncogene. 2006;25:795–805. doi: 10.1038/sj.onc.1209105. PubMed DOI

Tanno B, Sesti F, Cesi V, Bossi G, Ferrari-Amorotti G, Bussolari R, Tirindelli D, Calabretta B, Raschella G. Expression of slug is regulated by C-MYB and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem. 2010;285:29434–29445. doi: 10.1074/jbc.M109.089045. PubMed DOI PMC

Chen RX, Xia YH, Xue TC, Ye SL. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res. 2010;29:172. doi: 10.1186/1756-9966-29-172. PubMed DOI PMC

Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One. 2010;5:e13073. doi: 10.1371/journal.pone.0013073. PubMed DOI PMC

Ungefroren H, Groth S, Sebens S, Lehnert H, Gieseler F, Fandrich F. Differential roles of Smad2 and Smad3 in the regulation of TGF-beta1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1. Mol Cancer. 2011;10:67. doi: 10.1186/1476-4598-10-67. PubMed DOI PMC

Petrella BL, Brinckerhoff CE. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase. Mol Cancer. 2006;5:66. doi: 10.1186/1476-4598-5-66. PubMed DOI PMC

Sodek KL, Ringuette MJ, Brown TJ. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br J Cancer. 2007;97:358–367. doi: 10.1038/sj.bjc.6603863. PubMed DOI PMC

Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113–135. doi: 10.1016/S0009-8981(99)00224-7. PubMed DOI

Sodek KL, Brown TJ, Ringuette MJ. Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer. 2008;8:223. doi: 10.1186/1471-2407-8-223. PubMed DOI PMC

Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6:4823–4830. PubMed

Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2:252–257. doi: 10.1186/bcr65. PubMed DOI PMC

Benes P, Vetvicka V, Fusek M. Cathepsin D-many functions of one aspartic protease. Crit Rev Oncol Hematol. 2008;68:12–28. doi: 10.1016/j.critrevonc.2008.02.008. PubMed DOI PMC

Scott PG, Pearson H. Cathepsin D: specificity of peptide-bond cleavage in type-I collagen and effects on type-III collagen and procollagen. Eur J Biochem. 1981;114:59–62. PubMed

Handley CJ, Mok MT, Ilic MZ, Adcocks C, Buttle DJ, Robinson HC. Cathepsin D cleaves aggrecan at unique sites within the interglobular domain and chondroitin sulfate attachment regions that are also cleaved when cartilage is maintained at acid pH. Matrix Biol. 2001;20:543–553. doi: 10.1016/S0945-053X(01)00168-8. PubMed DOI

Cesi V, Casciati A, Sesti F, Tanno B, Calabretta B, Raschella G. TGFbeta-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER + breast cancer cells. Cell Cycle. 2011;10:4149–4161. doi: 10.4161/cc.10.23.18346. PubMed DOI

Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M. The functional -443 T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog. 2009;48:14–23. doi: 10.1002/mc.20452. PubMed DOI

Strohmaier AR, Spring H, Spiess E. Three-dimensional analysis of the substrate-dependent invasive behavior of a human lung tumor cell line with a confocal laser scanning microscope. Histochem Cell Biol. 1996;105:179–185. doi: 10.1007/BF01462290. PubMed DOI

Ehlers EM, Bakhshandeh A, Wiedemann G, Kuhnel W. Invasiveness of human pleural mesothelioma cells is influenced in vitro by the three-dimensional structure of the ECM and its composition. Ann Anat. 2002;184:417–424. doi: 10.1016/S0940-9602(02)80072-3. PubMed DOI

Saito K, Shimizu F, Sato T, Oite T. Modulation of human mesangial cell behaviour by extracellular matrix components-the possible role of interstitial type III collagen. Clin Exp Immunol. 1993;91:510–515. PubMed PMC

Tatti O, Arjama M, Ranki A, Weiss SJ, Keski-Oja J, Lehti K. Membrane-type-3 matrix metalloproteinase (MT3-MMP) functions as a matrix composition-dependent effector of melanoma cell invasion. PLoS One. 2011;6:e28325. doi: 10.1371/journal.pone.0028325. PubMed DOI PMC

Bhattarai G, Lee YH, Lee NH, Yun JS, Hwang PH, Yi HK. c-myb mediates inflammatory reaction against oxidative stress in human breast cancer cell line, MCF-7. Cell Biochem Funct. 2011;29:686–693. doi: 10.1002/cbf.1808. PubMed DOI

Khalkhali-Ellis Z, Hendrix MJ. Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res. 2007;67:3535–3539. doi: 10.1158/0008-5472.CAN-06-4767. PubMed DOI PMC

Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, Ness SA. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. Oncogene. 2003;22:308–313. doi: 10.1038/sj.onc.1206131. PubMed DOI

Rochefort H. Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer. 1992;28A:1780–1783. PubMed

Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene. 1990;5:1809–1814. PubMed

Masson O, Bach AS, Derocq D, Prebois C, Laurent-Matha V, Pattingre S, Liaudet-Coopman E. Pathophysiological functions of cathepsin D: Targeting its catalytic activity versus its protein binding activity? Biochimie. 2010;92:1635–1643. doi: 10.1016/j.biochi.2010.05.009. PubMed DOI

Abbott DE, Margaryan NV, Jeruss JS, Khan S, Kaklamani V, Winchester DJ, Hansen N, Rademaker A, Khalkhali-Ellis Z, Hendrix MJ. Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther. 2010;9:23–30. doi: 10.4161/cbt.9.1.10378. PubMed DOI PMC

Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res. 1993;53:873–877. PubMed

Glondu M, Liaudet-Coopman E, Derocq D, Platet N, Rochefort H, Garcia M. Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene. 2002;21:5127–5134. doi: 10.1038/sj.onc.1205657. PubMed DOI

Tedone T, Correale M, Barbarossa G, Casavola V, Paradiso A, Reshkin SJ. Release of the aspartyl protease cathepsin D is associated with and facilitates human breast cancer cell invasion. FASEB J. 1997;11:785–792. PubMed

Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. Depletion of procathepsin D gene expression by RNA interference: a potential therapeutic target for breast cancer. Cancer Biol Ther. 2007;6:1081–1087. doi: 10.4161/cbt.6.7.4325. PubMed DOI

Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. The propeptide of cathepsin D increases proliferation, invasion and metastasis of breast cancer cells. Int J Oncol. 2008;32:491–498. PubMed

Laurent-Matha V, Maruani-Herrmann S, Prebois C, Beaujouin M, Glondu M, Noel A, Alvarez-Gonzalez ML, Blacher S, Coopman P, Baghdiguian S. et al.Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J Cell Biol. 2005;168:489–499. doi: 10.1083/jcb.200403078. PubMed DOI PMC

Beaujouin M, Prebois C, Derocq D, Laurent-Matha V, Masson O, Pattingre S, Coopman P, Bettache N, Grossfield J, Hollingsworth RE. et al.Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J Cell Sci. 2010;123:3336–3346. doi: 10.1242/jcs.070938. PubMed DOI PMC

Li Y, Wood N, Grimsley P, Yellowlees D, Donnelly PK. In vitro invasiveness of human breast cancer cells is promoted by low density lipoprotein receptor-related protein. Invasion Metastasis. 1998;18:240–251. doi: 10.1159/000024517. PubMed DOI

Song H, Li Y, Lee J, Schwartz AL, Bu G. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. Cancer Res. 2009;69:879–886. doi: 10.1158/0008-5472.CAN-08-3379. PubMed DOI PMC

Dedieu S, Langlois B, Devy J, Sid B, Henriet P, Sartelet H, Bellon G, Emonard H, Martiny L. LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. Mol Cell Biol. 2008;28:2980–2995. doi: 10.1128/MCB.02238-07. PubMed DOI PMC

Tanno B, Negroni A, Vitali R, Pirozzoli MC, Cesi V, Mancini C, Calabretta B, Raschella G. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J Biol Chem. 2002;277:23172–23180. doi: 10.1074/jbc.M200141200. PubMed DOI

Bein K, Ware JA, Simons M. Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem. 1998;273:21423–21429. doi: 10.1074/jbc.273.33.21423. PubMed DOI

Smith CL, Hager GL. Transcriptional regulation of mammalian genes in vivo. A tale of two templates. J Biol Chem. 1997;272:27493–27496. doi: 10.1074/jbc.272.44.27493. PubMed DOI

Ko ER, Ko D, Chen C, Lipsick JS. A conserved acidic patch in the Myb domain is required for activation of an endogenous target gene and for chromatin binding. Mol Cancer. 2008;7:77. doi: 10.1186/1476-4598-7-77. PubMed DOI PMC

Wilczek C, Chayka O, Plachetka A, Klempnauer KH. Myb-induced chromatin remodeling at a dual enhancer/promoter element involves non-coding rna transcription and is disrupted by oncogenic mutations of v-myb. J Biol Chem. 2009;284:35314–35324. doi: 10.1074/jbc.M109.066175. PubMed DOI PMC

Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8:228. doi: 10.1186/1471-2407-8-228. PubMed DOI PMC

Fu SL, Ganter B, Lipsick JS. Myb proteins inhibit fibroblast transformation by v-Rel. Mol Cancer. 2006;5:54. doi: 10.1186/1476-4598-5-54. PubMed DOI PMC

Drabsch Y, Hugo H, Zhang R, Dowhan DH, Miao YR, Gewirtz AM, Barry SC, Ramsay RG, Gonda TJ. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells. Proc Natl Acad Sci USA. 2007;104:13762–13767. doi: 10.1073/pnas.0700104104. PubMed DOI PMC

Miao RY, Drabsch Y, Cross RS, Cheasley D, Carpinteri S, Pereira L, Malaterre J, Gonda TJ, Anderson RL, Ramsay RG. MYB is essential for mammary tumorigenesis. Cancer Res. 2011;71:7029–7037. doi: 10.1158/0008-5472.CAN-11-1015. PubMed DOI

Nicolau M, Levine AJ, Carlsson G. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational profile and excellent survival. Proc Natl Acad Sci USA. 2011;108:7265–7270. doi: 10.1073/pnas.1102826108. PubMed DOI PMC

Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol. 2010;30:3981–3993. doi: 10.1128/MCB.01284-09. PubMed DOI PMC

Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med. 2005;11:481–483. doi: 10.1038/nm1243. PubMed DOI

Wyatt CA, Geoghegan JC, Brinckerhoff CE. Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: effects on matrix destruction and tumor growth. Cancer Res. 2005;65:11101–11108. doi: 10.1158/0008-5472.CAN-05-2446. PubMed DOI

Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 2005;120:303–313. doi: 10.1016/j.cell.2004.12.018. PubMed DOI

Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4:909–914. doi: 10.1038/nm0898-909. PubMed DOI

Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A, Covic L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009;69:6223–6231. doi: 10.1158/0008-5472.CAN-09-0187. PubMed DOI PMC

Gupta GP, Nguyen DX, Chiang AC, Bos PD, Kim JY, Nadal C, Gomis RR, Manova-Todorova K, Massague J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature. 2007;446:765–770. doi: 10.1038/nature05760. PubMed DOI

Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518–524. doi: 10.1038/nature03799. PubMed DOI PMC

Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H. et al.Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA. 2007;104:6740–6745. doi: 10.1073/pnas.0701138104. PubMed DOI PMC

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massague J. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315–1326. doi: 10.1016/j.cell.2009.11.025. PubMed DOI PMC

Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 2008;133:66–77. doi: 10.1016/j.cell.2008.01.046. PubMed DOI PMC

Paku S, Dome B, Toth R, Timar J. Organ-specificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis. 2000;18:481–492. doi: 10.1023/A:1011858925376. PubMed DOI

Pugsley MK, Tabrizchi R. The vascular system. An overview of structure and function. J Pharmacol Toxicol Methods. 2000;44:333–340. doi: 10.1016/S1056-8719(00)00125-8. PubMed DOI

Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41–55. doi: 10.1007/s10555-007-9109-4. PubMed DOI

Arnold S, Mira E, Muneer S, Korpanty G, Beck AW, Holloway SE, Manes S, Brekken RA. Forced expression of MMP9 rescues the loss of angiogenesis and abrogates metastasis of pancreatic tumors triggered by the absence of host SPARC. Exp Biol Med (Maywood) 2008;233:860–873. doi: 10.3181/0801-RM-12. PubMed DOI PMC

de Vries JE, Dinjens WN, De Bruyne GK, Verspaget HW, van der Linden EP, de Bruine AP, Mareel MM, Bosman FT, ten Kate J. In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer. 1995;71:271–277. doi: 10.1038/bjc.1995.55. PubMed DOI PMC

Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal. 2011;9:18. doi: 10.1186/1478-811X-9-18. PubMed DOI PMC

Mareel MM, Van Roy FM, De Baetselier P. The invasive phenotypes. Cancer Metastasis Rev. 1990;9:45–62. doi: 10.1007/BF00047588. PubMed DOI

Bies J, Nazarov V, Wolff L. Identification of protein instability determinants in the carboxy-terminal region of c-Myb removed as a result of retroviral integration in murine monocytic leukemias. J Virol. 1999;73:2038–2044. PubMed PMC

Takahashi T, Suwabe N, Dai P, Yamamoto M, Ishii S, Nakano T. Inhibitory interaction of c-Myb and GATA-1 via transcriptional co-activator CBP. Oncogene. 2000;19:134–140. doi: 10.1038/sj.onc.1203228. PubMed DOI

Smarda J, Zemanova K, Bryja J, Smardova J, Kozubik A, Hofmanova J, Nemajerova A, Sevcikova S, Kohoutek J, Vodicka P. Retinoid X receptor suppresses transformation by the v-myb oncogene. J Leukoc Biol. 1999;66:1039–1048. PubMed

Wang F, Duan R, Chirgwin J, Safe SH. Transcriptional activation of cathepsin D gene expression by growth factors. J Mol Endocrinol. 2000;24:193–202. doi: 10.1677/jme.0.0240193. PubMed DOI

Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998;58:5321–5325. PubMed

Benanti JA, Williams DK, Robinson KL, Ozer HL, Galloway DA. Induction of extracellular matrix-remodeling genes by the senescence-associated protein APA-1. Mol Cell Biol. 2002;22:7385–7397. doi: 10.1128/MCB.22.21.7385-7397.2002. PubMed DOI PMC

Benes P, Maceckova V, Zdrahal Z, Konecna H, Zahradnickova E, Muzik J, Smarda J. Role of vimentin in regulation of monocyte/macrophage differentiation. Differentiation. 2006;74:265–276. doi: 10.1111/j.1432-0436.2006.00077.x. PubMed DOI

Smarda J, Sugarman J, Glass C, Lipsick J. Retinoic acid receptor alpha suppresses transformation by v-myb. Mol Cell Biol. 1995;15:2474–2481. PubMed PMC

Welch DR. Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis. 1997;15:272–306. doi: 10.1023/A:1018477516367. PubMed DOI

Tumor Cell-Intrinsic c-Myb Upregulation Stimulates Antitumor Immunity in a Murine Colorectal Cancer Model

Expression dynamics of metalloproteinases during mandibular bone formation: association with Myb transcription factor

Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors

Transcription factor c-Myb inhibits breast cancer lung metastasis by suppression of tumor cell seeding

Overexpression of c-Myb is associated with suppression of distant metastases in colorectal carcinoma

Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL

The Expression of c-Myb Correlates with the Levels of Rhabdomyosarcoma-specific Marker Myogenin